Clinipace Worldwide, a provider of clinical research services, has acquired Regulus Pharmaceutical Consulting, which is located in Boulder, Colo.

Financial terms were not disclosed.

The consulting team will remain based in Colorado.

Brenda Fielding, president at Regulus, will serve as executive vice president for regulatory affairs at Clilipace.

Regulus, an eight-year-old firm, focuses on regulatory affairs and strategic development. It will operate as a division of Clinipace.

“Regulus’ expertise is a strategic fit for Clinipace Worldwide as they provide a unique resource of experience and skills to meet the requirements of our biopharmaceutical and medical device clients,” said Jeff Williams, chief executive officer at Clinipace.

“Industry leadership and expertise from Regulus fuels our mission of partnering with our clients in bringing innovative therapies to market through our technology-amplified services in clinical development, regulatory affairs, and strategic development,” he added.

Since it is privately held, Clinipace won’t provide specific revenue numbers, but the company says its revenues doubled from 2009 and are up more than 800 percent over the past two years. 2010 was its “best year to date” with 12 new clients and 16 additional projects.

Some numbers about Clinipace are known, however. In the Inc 500 list of the 500 fastest-growing companies announced last September, Clinipace reported revenues were up 614 percent to $5.1 million from the previous year.

Clinipace touts itself as a “digital” CRO with a proprietary “e-clinical” platform for clinical trials and research work. New projects include Phase I, II and III clinical trials ranging from oncology to immunology plus regulatory consulting and biostatisical work.

Founded in 2004, it raised more than $2 million in venture capital funding two years ago to finance growth initiatives. In 2009, it acquired a competitor in Kansas and added Worldwide to the company name.

For more about Clinipace, read WRAL Tech Wire’s report here.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.